London, United Kingdom-Thursday 29 April 2021 [ AETOS Wire ]
Hikma Pharmaceuticals PLC (Hikma) and Melinta Therapeutics (Melinta) today announced they have entered into an exclusive licensing agreement for Vabomere® (meropenem and vaborbactam) and Orbactiv® (oritavancin), two novel anti-infective injectable products, for the Middle East and North Africa (MENA) region.
In the United States, Orbactiv® is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections due to designated susceptible Gram-positive pathogens and Vabomere® is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections, including pyelonephritis, caused by designated susceptible Gram-negative pathogens.
Under the terms of the agreement, Hikma is responsible for the registration and commercialisation of these two products across its 18 MENA markets. This extends Hikma’s existing partnership with Melinta for their intravenous and oral formulations of Baxdela® (delafloxacin), a novel antibiotic product. The addition of these two innovative products to Hikma’s portfolio builds on its hospital anti-infective franchise and provides healthcare professionals with more treatment options.
“We are excited to be extending our partnership with Melinta and bring Vabomere® and Orbactiv® to our patients in MENA,” said Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA. “As one of the leading suppliers in the region, it is our responsibility to equip doctors with the latest and most innovative developments to treat their patients. This agreement supports our strategy of establishing a global network of partners to strengthen our portfolio and improve availability of treatment options in the MENA region.”
“Hikma shares our commitment to ensure that all patients who need our life-saving therapies can get them,” said Christine Ann Miller, President and Chief Executive Officer of Melinta. “We’re thrilled to extend our partnership to reach patients in need in the MENA region with Vabomere® and Orbactiv®.”
Contacts
Hikma Pharmaceuticals PLC
Susan Ringdal
EVP, Strategic Planning and Global Affairs
+44 (0)20 7399 2760/ +44 7776 477050
uk-investors@hikma.uk.com
Dana Alhusseini
Communication Manager
+962 6 580 2900
Dalhusseini@hikma.com
Melinta Therapeutics
Susan Blum
Interim Chief Financial Officer
+1 312 767 0296
info@melinta.com
Permalink : https://www.aetoswire.com/news/hikma-and-melinta-therapeutics-sign-exclusive-licensing-agreement-for-two-novel-anti-infectives-for-the-middle-east-and-north-africa-region/en
